一种分次剂量并不适合所有人:基于离散选择实验的患者对低分次放射治疗偏好
本研究采用离散选择实验,纳入2019年在本学术癌症中心接受外照射放疗的58例局限期前列腺癌患者,评估其对常规、中度低分次和立体定向放疗方案在便利性、疗效和毒性风险方面的偏好。结果显示所有属性均显著影响选择,前列腺特异性抗原复发风险、晚期和急性毒性最重要,年龄较大和农村患者显著偏好更短疗程且不愿延长治疗以降低毒性风险。
要点
- 前列腺特异性抗原复发风险、晚期毒性和急性毒性是患者最重视的属性。
- 年龄较大和农村患者显著偏好更短的外照射放疗疗程。
- 部分患者愿意以增加毒性风险换取更方便的治疗方案。
核心结论
- 前列腺癌患者重视外照射放疗的属性,部分患者愿意以增加毒性风险换取更好的便利性。
- 研究结果促进共享临床决策,因为患者有兴趣了解相关的权衡取舍。
研究设计与样本
- 采用离散选择实验,自愿样本为在本学术癌症中心接受外照射放疗的局限期前列腺癌患者。
- 2019年共58名参与者同意完成面对面1:1离散选择实验,平均(标准差)年龄72.9(7.1)岁。
- 每名参与者需在2个独特的外照射放疗场景间做出12次选择,每个场景由5个属性描述:治疗时间、基准标记物植入、前列腺特异性抗原复发风险、急性和晚期胃肠道或泌尿生殖系统毒性风险。
- 患者偏好采用混合多项逻辑回归估计,预设亚组采用条件逻辑回归。
主要发现
- 所有属性均具有统计学显著性,影响参与者的选择。
- 前列腺特异性抗原复发风险(β=-2.581)、晚期毒性(β=-1.854)和急性毒性(β=-1.005)对参与者最重要(每项P<.001)。
- 外照射放疗疗程长度(β=-0.728;P=.017)和基准标记物植入(β=-0.563;P=.004)次之。
- 年龄较大(β=-0.063;95%置信区间-0.12,-0.01)和农村(β=-0.083;95%置信区间-0.14,-0.02)参与者显著偏好更短的外照射放疗,且更不愿意延长治疗以降低毒性风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Hypofractionated external beam radiation therapy (EBRT) is a standard of care option for localized prostate cancer. To inform clinical practice we quantified patients' preferences for convenience, efficacy, and toxicity risks, of conventional, moderate hypofractionation, and stereotactic radiation therapy regimens. METHODS AND MATERIALS: We used a discrete choice experiment with a voluntary sample consisting of patients treated with EBRT for localized prostate cancer at our academic cancer center. In 2019, 58 participants, mean (SD) age of 72.9 (7.1) years, agreed to complete an in-person 1:1 discrete choice experiment. Each participant made 12 choices between 2 unique EBRT scenarios, each described by 5 attributes: (1) treatment time; (2) fiducial markers; and risk of (3) prostate specific antigen recurrence; (4) acute and (5) late GI or GU toxicity. Patient preferences were estimated using mixed multinomial logistic regression, and prespecified subgroups with conditional logistic regression. RESULTS: All attributes were statistically significant, thus influenced participants' choices. Risks of prostate specific antigen recurrence (β = -2.581), late (β = -1.854), and acute (β = -1.005) toxicity were most important to participants (P < .001 for each), followed by EBRT length (β = -0.728; P = .017) and fiducial marker implantation (β = -0.563; P = .004). Older (β = -0.063; 95% confidence interval, -0.12, -0.01) and rural (β = -0.083; 95% CI -0.14, -0.02) participants significantly preferred shorter EBRT and were less willing-to-extend treatment to reduce toxicity risk. CONCLUSIONS: Patients with prostate cancer place importance on EBRT attributes, and some are willing to trade-off increased risk of toxicity for improved convenience. Our findings promote shared clinical decision-making because patients are interested in learning about the trade-offs involved.
引用
- Sigurdson S, Harrison M, Pearce A, et al. One Fraction Size Does Not Fit All: Patient Preferences for Hypofractionated Radiation Therapy From a Discrete Choice Experiment. Pract Radiat Oncol. 2022. PMID: 34991857. doi:10.1016/j.prro.2021.08.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。